Melis McHenry

Company: Regeneron

Job title: Associate Director, Precision Medicine CDx

Seminars:

Considerations for Strategy, Regulatory Requirements, Implementation & Commercialization of a NASH CDx Assay 11:30 am

The global prevalence of Nonalcoholic steatohepatitis, or NASH, is increasing with over 5% of the general population affected. If untreated, NASH may progress to liver cirrhosis, liver carcinoma, and death Numerous risk factors influence the development of NASH, including genetic predisposition. We initiated an investigational trial for a hepatocyte-targeted siRNA approach in NASH A clinical…Read more

day: Day 1 Track C AM